<DOC>
	<DOCNO>NCT02711462</DOCNO>
	<brief_summary>This Phase 1 study double blind , third party open ( ie , subject blind , investigator blind Sponsor open ) , randomize , placebo control , single multiple dose escalation study healthy subject , female non childbearing potential male age 18 55 year , inclusive . There may 11 Cohorts study . Approximately 7 cohort anticipate Single Dose ( SD ) portion study 4 cohort anticipate Multiple Dose ( MD ) portion study . Following last subject Day 28 visit first two single dose cohort ( Cohorts 1 2 ) , available data inclusive Day 28 evaluate PK , immunogenicity , safety tolerability . FDA review agreement move forward take place remain single dose cohort multiple dose phase ( Cohorts 3 11 ) initiate . A total approximately 82 subject anticipate enrol study . The duration dose multiple dose cohort would 4 week regimen may include weekly ( total 5 dos ) , every 2 week ( total 3 dos ) monthly dose ( total two dos ) .</brief_summary>
	<brief_title>Study Healthy Subjects Evaluate Safety , Tolerability , Pharmacokinetics Pharmacodynamics PF-06687234</brief_title>
	<detailed_description />
	<criteria>INCLUSION CRITERIA Healthy females non childbearing potential healthy male No evidence active latent inadequately treated infection Mycobacterium tuberculosis ( TB ) Ability personally sign date inform consent document able comply schedule activity For Single Dose Cohort 7 , Japanese subject must four biological Japanese grandparent born Japan . EXCLUSION CRITERIA Evidence history clinically significant health concern Treatment investigational drug within 30 day Exposure live vaccine within 28 day prior investigational product administration . History drug and/ alcohol abuse tobacco use equivalent 5 cigarette per day . Known history infection hepatitis B virus , hepatitis C virus , human immunodeficiency virus Pregnant female subject History sensitivity heparin Unwilling unable comply Lifestyle Guidelines state protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Healthy Subjects</keyword>
</DOC>